Immunopathogenesis: Insights for current and future therapies
John M. Vierling – 5 March 2014 – Watch a video presentation of this article
Treatment of primary biliary cirrhosis: Is there more to offer than ursodeoxycholic acid?
Albert Parés – 5 March 2014
Autoimmune hepatitis: Histopathology
Stephen A. Geller – 5 March 2014
Reply
Jamuna Karkhanis, Elizabeth C. Verna, Matthew S. Chang, R. Todd Stravitz, Michael L. Schilsky, William M. Lee, Robert S. Brown – 5 March 2014
Historical, present, and future significance of corticosteroid in the treatment of acute liver failure
Keiichi Fujiwara, Shin Yasui, Osamu Yokosuka – 4 March 2014
Reply
Martin Lagging, Karolina Rembeck, Jesper Waldenström, Staffan Nilsson, Kristina Nyström, Anna Martner, Magnus Lindh, Gunnar Norkrans, Johan Westin, Court Pedersen, Martti Färkkilä, Nina Langeland, Mads Rauning Buhl, Kristine Mørch, Peer B. Christensen, Kristoffer Hellstrand – 4 March 2014
Variants of the inosine triphosphate pyrophosphatase gene and relapse risk following treatment for HCV genotype 2/3
Chia‐Yen Dai, Wan‐Long Chuang, Ming‐Lung Yu – 4 March 2014
FDA bridging analyses confirmed in clinical trial
Poonam Mishra, Jeffry Florian, Jeffrey Murray – 2 March 2014
Reply
Ju Dong Yang, Ayako Suzuki – 28 February 2014
Late HDV RNA relapse after peginterferon alpha‐based therapy of chronic hepatitis delta
Benjamin Heidrich, Cihan Yurdaydın, Gökhan Kabaçam, Boris A. Ratsch, Kalliopi Zachou, Birgit Bremer, George N. Dalekos, Andreas Erhardt, Fehmi Tabak, Kendal Yalcin, Selim Gürel, Stefan Zeuzem, Markus Cornberg, C.‐Thomas Bock, Michael P. Manns, Heiner Wedemeyer, HIDIT‐1 Study Group – 28 February 2014 – Interferon alpha is the only treatment option for hepatitis delta virus (HDV). Trials investigating the efficacy of pegylated interferon alpha (PEG‐IFNa) showed HDV RNA negativity rates of 25‐30% 24 weeks after therapy.